Results 221 to 230 of about 72,525 (247)

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Blood, 2009
Van Eygen Koen, Tara A Albrecht, Pierre Zachee   +2 more
exaly  

Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases

Journal of Controlled Release, 2012
Robbert Jan, W E Hennink
exaly  

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Blood, 2007
Timothy Hughes, Hagop Kantarjian, Tadeusz Robak   +2 more
exaly  

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

Cancer, 2009
David Dejardin, Jorge Cortes, Timothy Hughes   +2 more
exaly  

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

Annals of Oncology, 2011
Nicolas Penel, Jean-Yves Blay, C Guillemet   +2 more
exaly  

Imatinib

Reactions Weekly, 2019
  +4 more sources

Dysregulation of bone remodeling by imatinib mesylate

Blood, 2010
Timothy Hughes, Kate Vandyke, Andrew Zannettino   +2 more
exaly  

Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients

Annals of Oncology, 2011
Teun van Gelder, Milena Soriano Marcolino   +1 more
exaly  

Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma

Annals of Oncology, 2013
Marta Giorgia Podda, Alberto Garaventa, Roberto Luksch   +2 more
exaly  

Imatinib

Reactions Weekly, 2023
openaire   +1 more source